department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Lonsurf · pharmadog

pharmadog
drugs
Lonsurf

drug

patient view →

(tipiracil hydrochloride + trifluridine)

Marketedupdated 2mo ago

by Taiho Oncology Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Lonsurf

generic

(tipiracil hydrochloride + trifluridine)

indication

Adenocarcinoma Of The Gastroesophageal Junction

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 22, 2029

~3.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Feb 3, 2037method-of-use (U-3658)US 10456399
Feb 3, 2037method-of-use (U-3657)US 10456399
Feb 3, 2037method-of-use (U-3658)US 10960004
Feb 3, 2037method-of-use (U-3658)US 10960004
Sep 5, 2034method-of-use (U-3659)US 9943537
Sep 5, 2034method-of-use (U-3659)US 9943537
Jun 17, 2034compositionUS 10457666
Jun 17, 2034compositionUS 10457666
Jun 17, 2034compositionUS 9527833
Jun 17, 2034compositionUS 9527833
Sep 22, 2029method-of-use (U-3656)US RE462843.2y
Sep 22, 2029method-of-use (U-3656)US RE462843.2y

FDA exclusivities (2)

Feb 22, 2026ODE-229Orphan Drug (7y)
Feb 22, 2026ODE-229Orphan Drug (7y)

Trials studying (tipiracil hydrochloride + trifluridine)

N/ABioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humanscompletedn=76
phase2A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancerrecruitingn=120
phase2Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancerrecruitingn=73
—An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditionscompletedn=818
phase1A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumorsrecruitingn=130
phase2Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinomacompletedn=28
phase1Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)terminatedn=14